HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E2964 Norepinephrine tartrate Norepinephrine tartrate is a potent agonist of adrenergic receptor (AR). Norepinephrine activates α1, α2, β1 receptors. Jun 28 2023
E2950 Fat Emulsion（20%） Fat Emulsion（20%）is a safe fat emulsion that can be used as a nutritional supplement. Fat Emulsion（20%）inhibits the opening of the mitochondrial permeability transition pore and effectively protecting the heart from ischaemia-reperfusion injury. It has some potential to modulate the innate immune response. Jun 28 2023
E1217 PCLX-001 (DDD86481) PCLX-001 (DDD86481) is an orally active dual N-myristoyltransferase (NMT) inhibitor. It inhibits NMT1 and NMT2 with IC50 of 5 nM and 8 nM, respectively, in vitro. PCLX-001 inhibits early B-cell receptor (BCR) signalling, which can be used in B-cell malignancy research. Jun 28 2023
E2969 Mannan Mannan is one of the major components of the yeast cell wall. It can be used to coat the microtiter wells to quantify the levels of mannose-binding lectin (MBL) using a mannan-binding enzyme-linked immunosorbent assay (ELISA). Mannan exhibits antiproliferative, antioxidant, and immunomodulatory properties. Jun 28 2023
A2053 Monalizumab (Anti-Human CD159a) Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. Jun 28 2023
D4026 Tusamitamab ravtansine Tusamitamab Ravtansine (SAR-408701), is an antibody-drug conjugate (ADC) composed of CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule ) targeting antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. TUSAMITAMAB RAVTANSINE has the potential for use in research of several solid tumors. Jun 27 2023
D4027 Serclutamab talirine Serclutamab Talirine (ABBV-321), is an antibody-drug conjugate (ADC) composed of an humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a maleimidocaproyl-valine-alanine linker. Serclutamab Talirine has the potential for use in advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands. Jun 27 2023
D4030 Vadastuximab talirine Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients. Jun 27 2023
D4031 Cantuzumab mertansine Cantuzumab mertansine (HUC242-DM1, SB-408075) is an anti-MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242), humanized monoclonal antibody conjugated to maytansinoid DM1 ([N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)-maytansine]) via a reductible SPP linker [N-succinimidyl 4-(2-pyridyldithio)pentanoate]. Jun 27 2023
D4032 Cantuzumab ravtansine Cantuzumab ravtansine (IMGN242, HUC242-DM4) is an ADC. It is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts. Jun 27 2023
D4033 Ozuriftamab vedotin Ozuriftamab vedotin (BA 3021) is an antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity. Jun 27 2023
D4034 Lorvotuzumab mertansine Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). Jun 27 2023
D4036 Sofituzumab vedotin Sofituzumab Vedotin (DMUC5754A, RG-7458) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody (mAb) and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker. DMUC5754A binds to the MUC16 extracellular domain with high affinity. Jun 27 2023
D4037 Laprituximab emtansine Laprituximab emtansine (IMGN-289) is an anti-EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB), chimeric monoclonal antibody conjugated to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker, forming a nonreducible thioether bond. Jun 27 2023
D4038 Enapotamab vedotin Enapotamab vedotin (EnaV, HuMAX-AXL-ADC) is an AXL-specific human IgG1 antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) through a protease cleavable valine-citrulline (vc) linker. Jun 27 2023
D4039 Praluzatamab ravtansine Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. Jun 27 2023
E1383 Cp2-SO4 Cp2-SO4 is a phenylalanine derivative which reverses interleukin 4 induced 1 (IL4I1)-dependet inhibition of T-cell proliferation with Ki of 21.2 µM. Jun 26 2023
E1313 N-Formyl-Met-Leu-Phe (fMLP) N-Formyl-Met-Leu-Phe (fMLP) is an endogenous chemotactic peptide and agonist for the formyl peptide receptor 1 (FPR1) with Ki of 38 nM. It stimulates aggregation of leukocytes. Jun 26 2023
E2951 D-Desthiobiotin D-Desthiobiotin(Dethiobiotin) is a biotin derivative used in affinity chromatography and protein chromatography. D-Desthiobiotin also can be used for protein cross-linking agent, protein and cell labeling, detection and isolation. Jun 26 2023
D4006 Anetumab-MMAE Anetumab-MMAE is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin (MSLN) antibody and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). Jun 26 2023